ABSTRACT
Cancer therapies, such as chemotherapy, radiotherapy (RT), targeted therapies, hormone therapy, and recently immunotherapy, have managed to increase the survival of patients diagnosed with this disease, being increasingly specific and effective, thus achieving an increase in life expectancy and, in some cases, turning cancer into a chronic pathology [1]. Despite these great advances, antineoplastic treatments present a series of dermatological adverse effects (DAEs) [2], considerably affecting quality of life (QoL), self-esteem, social life, work life, and relationships [3], and are also an impediment to proper fulfillment and adherence to treatment to such an extent that it is sometimes necessary to interrupt treatment, with a negative impact on the evolution and prognosis of the disease [4]. Several studies have shown that DAEs can have a negative impact on the QoL of cancer patients, while others have emphasized the psychological effects, such as depression, anxiety, and vulnerability. Identifying and developing prevention plans and individual treatment according to what each patient needs is essential to improve the QoL of this group and its subsequent sequelae [3].
